David Lebowitz
Stock Analyst at Citigroup
(3.87)
# 673
Out of 4,979 analysts
119
Total ratings
59.77%
Success rate
7.25%
Average return
Main Sectors:
Stocks Rated by David Lebowitz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Maintains: Buy | $69 → $84 | $63.18 | +32.95% | 14 | Sep 3, 2025 | |
| CYTK Cytokinetics | Maintains: Buy | $77 → $84 | $50.76 | +65.50% | 4 | Sep 2, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Buy | $56 → $48 | $24.38 | +96.88% | 2 | Aug 20, 2025 | |
| SDGR Schrödinger | Downgrades: Neutral | $35 → $20 | $19.04 | +5.04% | 10 | Aug 15, 2025 | |
| ASND Ascendis Pharma | Maintains: Buy | $243 → $290 | $201.30 | +44.07% | 14 | Aug 8, 2025 | |
| INCY Incyte | Maintains: Buy | $88 → $103 | $85.44 | +20.55% | 6 | Jul 30, 2025 | |
| VKTX Viking Therapeutics | Maintains: Neutral | $31 → $38 | $25.61 | +48.38% | 2 | Jul 24, 2025 | |
| COGT Cogent Biosciences | Maintains: Buy | $15 → $22 | $12.75 | +72.55% | 4 | Jul 18, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $58 → $67 | $53.24 | +25.85% | 5 | Jul 11, 2025 | |
| EXEL Exelixis | Maintains: Buy | $45 → $56 | $38.20 | +46.60% | 3 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $10 | $11.88 | -15.82% | 8 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $1.5 | $1.79 | -16.20% | 6 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $32 → $45 | $58.58 | -23.18% | 4 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $68 | $77.05 | -11.75% | 4 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $382 | $448.30 | -14.79% | 1 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $103 → $96 | $54.64 | +75.70% | 3 | Jun 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $18 → $12 | $8.10 | +48.15% | 2 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $170 → $164 | $467.11 | -64.89% | 7 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 → $39 | $17.53 | +122.48% | 6 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $21 | $16.16 | +29.95% | 11 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $435 → $405 | $6.47 | +6,159.66% | 1 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $13 → $14 | $1.09 | +1,184.40% | 2 | Oct 12, 2021 |
Ionis Pharmaceuticals
Sep 3, 2025
Maintains: Buy
Price Target: $69 → $84
Current: $63.18
Upside: +32.95%
Cytokinetics
Sep 2, 2025
Maintains: Buy
Price Target: $77 → $84
Current: $50.76
Upside: +65.50%
Celldex Therapeutics
Aug 20, 2025
Maintains: Buy
Price Target: $56 → $48
Current: $24.38
Upside: +96.88%
Schrödinger
Aug 15, 2025
Downgrades: Neutral
Price Target: $35 → $20
Current: $19.04
Upside: +5.04%
Ascendis Pharma
Aug 8, 2025
Maintains: Buy
Price Target: $243 → $290
Current: $201.30
Upside: +44.07%
Incyte
Jul 30, 2025
Maintains: Buy
Price Target: $88 → $103
Current: $85.44
Upside: +20.55%
Viking Therapeutics
Jul 24, 2025
Maintains: Neutral
Price Target: $31 → $38
Current: $25.61
Upside: +48.38%
Cogent Biosciences
Jul 18, 2025
Maintains: Buy
Price Target: $15 → $22
Current: $12.75
Upside: +72.55%
BridgeBio Pharma
Jul 11, 2025
Maintains: Buy
Price Target: $58 → $67
Current: $53.24
Upside: +25.85%
Exelixis
May 15, 2025
Maintains: Buy
Price Target: $45 → $56
Current: $38.20
Upside: +46.60%
May 9, 2025
Maintains: Neutral
Price Target: $14 → $10
Current: $11.88
Upside: -15.82%
Mar 4, 2025
Maintains: Neutral
Price Target: $4 → $1.5
Current: $1.79
Upside: -16.20%
Feb 12, 2025
Maintains: Sell
Price Target: $32 → $45
Current: $58.58
Upside: -23.18%
Nov 13, 2024
Maintains: Buy
Price Target: $65 → $68
Current: $77.05
Upside: -11.75%
Mar 6, 2024
Initiates: Buy
Price Target: $382
Current: $448.30
Upside: -14.79%
Jun 30, 2023
Maintains: Neutral
Price Target: $103 → $96
Current: $54.64
Upside: +75.70%
Jul 15, 2022
Maintains: Equal-Weight
Price Target: $18 → $12
Current: $8.10
Upside: +48.15%
Jul 15, 2022
Maintains: Equal-Weight
Price Target: $170 → $164
Current: $467.11
Upside: -64.89%
Jun 7, 2022
Maintains: Overweight
Price Target: $36 → $39
Current: $17.53
Upside: +122.48%
Oct 12, 2021
Maintains: Equal-Weight
Price Target: $20 → $21
Current: $16.16
Upside: +29.95%
Oct 12, 2021
Maintains: Overweight
Price Target: $435 → $405
Current: $6.47
Upside: +6,159.66%
Oct 12, 2021
Maintains: Equal-Weight
Price Target: $13 → $14
Current: $1.09
Upside: +1,184.40%